About Replimune

Our Science

Oncolytic immunotherapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumors, while at the same time inducing a potent, patient-specific, anti-tumor immune response. Oncolytic viruses have the unique ability to generate an autologous immune response to the patient’s particular complement of tumor antigens, including neoantigens, with a truly off-the-shelf approach. While clear single agent clinical activity has been achieved with oncolytic immunotherapy, it is anticipated that enhanced efficacy may be seen in combination with other cancer therapies, including immune checkpoint blockade.